Genetic and Genomic Insights into the Molecular Basis of Atherosclerosis  by Chen, Yaoyu et al.
Cell Metabolism
ReviewGenetic and Genomic Insights into
the Molecular Basis of Atherosclerosis
Yaoyu Chen,1 Jarod Rollins,1 Beverly Paigen,1 and Xiaosong Wang2,*
1The Jackson Laboratory, Bar Harbor, ME 04609, USA
2Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
*Correspondence: xiaosong.wang@novartis.com
DOI 10.1016/j.cmet.2007.07.001
Atherosclerosis is a complex disease involving genetic and environmental risk factors, acting on their
own or in synergy. Within the general population, polymorphisms within genes in lipid metabolism,
inflammation, and thrombogenesis are probably responsible for the wide range of susceptibility to
myocardial infarction, a fatal consequence of atherosclerosis. Genetic linkage studies have been car-
ried out in both humans andmousemodels to identify these polymorphisms. Approximately 40 quan-
titative trait loci for atherosclerotic disease have been found in humans, and approximately 30 in
mice. Recently, genome-wide association studies have been used to identify atherosclerosis-
susceptibility polymorphisms. Although discovering new atherosclerosis genes through these
approaches remains challenging, the pace at which these polymorphisms are being found is accel-
erating due to rapidly improving bioinformatics resources and biotechnologies. The outcome of
these efforts will not only unveil themolecular basis of atherosclerosis but also facilitate the discovery
of drug targets and individualized medication against the disease.Introduction
Atherosclerosis is characterized by lipid accumulation, in-
flammatory response, cell death, and fibrosis in the arterial
wall. Our understanding of the pathogenesis of this pro-
cess has evolved in the last few decades, guiding our ef-
forts to find treatments. Because low-density lipoprotein
cholesterol (LDL-C) is proatherogenic, statin drugs were
developed to lower plasma LDL-C levels and reduce the
risk of adverse cardiovascular events. Recent studies
suggest that reducing LDL-C levels to below current
guideline targets further inhibits atherogenesis and re-
duces adverse coronary events (Todd and Farmer,
2006). Statin drugs have reduced new adverse cardiovas-
cular events by one-third; although this is significant, it is
clear that additional therapies are needed. Based on
a plethora of evidence suggesting that increasing plasma
high-density lipoprotein cholesterol (HDL-C) levels inhibits
atherogenesis, HDL-raising agents are expected to retard
atherogenesis. Three classes of HDL-raising agents exist:
niacin, fibrate, and statin. Promising new classes include
apoA-I phospholipid complexes, human apoA-I and
apoA-I mimetic peptides, and inhibitors of cholesteryl es-
ter transfer protein (CETP), although results from torcetra-
pib still leave a number of questions open (Brousseau,
2005). New HDL-raising targets are being sought with
genetics and genomics approaches (Rollins et al., 2006;
Wang and Paigen, 2005a). The relatively recent apprecia-
tion that inflammatory response plays a key role in athero-
genesis implies that inhibiting inflammation may provide
new antiatherosclerosis therapy. However, immune re-
sponse can both promote and retard atherosclerosis
(Hansson and Libby, 2006). The challenge will be to inhibit164 Cell Metabolism 6, September 2007 ª2007 Elsevier Inc.atherosclerosis-specific inflammation without compro-
mising global immune responses.
To better understand the molecular mechanisms of ath-
erogenesis, twomajor approaches have been undertaken.
The first is the candidate gene approach, in which genes in
known atherogenesis pathways are tested for their role in
atherosclerosis in vitro, in vivo, and in association studies.
This approach has been fruitful, and the role of many
genes in atherogenesis has become known as a result
(Arnett et al., 2007; Hansson and Libby, 2006; Lusis
et al., 2004). The second approach is the use of genome-
wide linkage studies to find atherogenesis-regulating
quantitative trait loci (QTLs). This is an unbiased method
that has the potential to find new atherosclerosis genes.
Recently, the availability of whole-genome sequences in
humans and mice, especially abundant single-nucleotide
polymorphism (SNP) and haplotype information, has
made it possible to perform genome-wide association
studies, another unbiased approach, to identify disease
genes relatively quickly as compared with traditional ge-
netic methods. Indeed, the pace at which disease genes
arebeing foundusing such unbiasedmethodshas acceler-
ated greatly in recent years because of ever improving
SNP/haplotype information, experimental design, statisti-
cal methods, and the decreasing cost of high-throughput
sequencing. In this review, we focus on finding novel ath-
erosclerosis-regulating genes using genome-wide linkage
and association studies, summarize examples of the
successful use of these approaches, and present detailed
human-mouse comparative genomics maps of known
atherosclerosis-regulating QTLs, which should be useful
in the search for new atherosclerosis-regulating genes.
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Diseases in Humans
Atherosclerotic disease linkage studies have been con-
ducted in 19 human populations (Table 1). Four of these
studies were for linkage to coronary artery disease
(CAD), six for linkage to myocardial infarction (MI), one
for linkage to both CAD and MI, one for linkage to acute
coronary syndrome (ACS), two for linkage to carotid
intimal-medial thickness (CIMT), two for linkage to coro-
nary artery calcification (CAC), two for linkage to stroke,
and one for linkage to peripheral arterial occlusive disease
(PAOD). Forty atherosclerotic disease-regulating QTLs
have been identified: 9 for CAD, 12 for MI, 1 for CAD/MI,
3 for ACS, 9 for CIMT, 4 for CAC, 1 for stroke, and 1 for
PAOD. Two meta-analyses of these genome-wide linkage
analyses have been reported: in a meta-analysis of four
studies, two linkage regions (2q and 3q) in the original
studies were confirmed (Chiodini and Lewis, 2003); in an-
other meta-analysis of five studies, four linkage regions in
the original studies (1p, 5p, 12q, and 13q) were confirmed,
while four new linkage regions that were not found in the
original studies (6p, two on 8q, and 14p) were revealed
(Zintzaras and Kitsios, 2006). It is noteworthy that among
the 40 human atherosclerosis QTLs, only three are repli-
cated in more than one population for the same disease:
one CAD QTL on chromosome (chr) 2, one stroke QTL
on chr 5, and one MI QTL on chr 17. However, when all
seven disease types are considered together as ‘‘athero-
sclerotic disease,’’ then there are 33 QTL regions, 11 of
which are replicates (Figure 1). This relatively low replicate
rate is possibly due to the small sample size and popula-
tion difference in many studies. By using methods dis-
cussed previously (Rollins et al., 2006), we found that 31
of the 40 human QTLs are concordant with mouse QTLs
(Figure 1), suggesting that identifying the genes underlying
the mouse QTLs will facilitate identifying the genes under-
lying the human QTLs.
Putative disease genes have been found from only three
QTLs for atherosclerotic disease, but the pace at which
these genes are identified is expected to accelerate (Far-
rall et al., 2006; Hakonarson et al., 2005). The deCODE
Genetics group in Iceland mapped a QTL for both MI
and stroke to chr 13q12–13 and subsequently identified
5-lipoxygenase-activating protein (ALOX5AP, also called
FLAP) as the underlying gene (Helgadottir et al., 2004).
ALOX5AP contributes to the conversion of ALOX5 in the
leukotriene pathway, yielding to production of leukotriene
B4 (LTB4), one of the most potent leukocyte proinflamma-
tory mediators. This finding is consistent with the discov-
ery that 5-lipoxygenase (Alox5) is the underlying gene for
an atherosclerosis QTL on mouse Chr 6 and that the
ALOX5/ALOX5AP pathway influences the development
of atherosclerosis (discussed below). In another study,
Wang et al. (2003a) studied a large family with 13 mem-
bers who displayed an autosomal dominant pattern of
CAD, 9 of whomdeveloped acuteMI. They found a linkage
of CAD/MI to a region on 15q26, which consists of 93
genes. One of the genes, myocyte-enhancing factor
2A (MEF2A), is expressed in endothelial cells (ECs) ofcoronary arteries. A 21 base-pair deletion was identified
in exon 11 in all ten living family members with CAD, and
not in family members and an additional 119 individuals
with normal angiograms, strongly suggesting that this de-
letion is responsible for CAD and MI in this large family
(Wang et al., 2003a). MEF2A mutations may be a rare
cause of CAD and MI, because they were present in less
than 2% of a US population of 207 CAD/MI patients (Bha-
gavatula et al., 2004). Later, in another two studies, the 21
base-pair deletion was found in a total of six subjects
(three in each study) older than 60 years of age who had
no history or symptoms of CAD (Kajimoto et al., 2005b;
Weng et al., 2005), which seems to argue against the cau-
sality of the 21 base-pair deletion in CAD/MI (Altshuler and
Hirschhorn, 2005). However, in these later two studies, the
CAD status in control subjects was not confirmed with an-
giography, as it had been in the originalWang et al. (2003a)
publication, making the conclusion not definitive. A recent
study found that a P279L variant of MEF2A is associated
with the risk of MI (11 of 483, or 2.3%, in MI patients; 9
of 1189, or 0.8%, in controls; odds ratio [OR] = 3.06) (Gon-
zalez et al., 2006). In this study, the CAD status in controls
was not confirmed with angiography either; however, this
might add to the strength of the association because
some of the nine ‘‘controls’’ with the variant, all of whom
were under 50 years of age,may yet developMI at an older
age. More recently, association studies were performed
for candidate genes in the 1-LOD (logarithm of the odds
ratio) supporting interval of the 3q13 QTL for CAD that
Hauser et al. (2004) identified, and the authors found
that four closely located genes on chr 3 were associated
with the risk for CAD: CDGAP at 120.5 Mb, MYLK at
124.8 Mb, and KALRN at 125.3 Mb in one study (Wang
et al., 2007), and GATA2 at 129.7 Mb in another study
(Connelly et al., 2006). The first three are all part of the
GTPase-signaling pathway. How these genes affect
CAD risk is not clear, although KALRN inhibits inducible
nitric oxide synthase, and GATA1 may affect endothelial
functions.
Genetic Linkage Studies of Atherosclerosis
in Mice
The three most commonly used mouse models of athero-
sclerosis are the following: (1) a high-fat model in which
inbred mice are fed a high-fat and high-cholesterol diet
(15% fat, 1.25% cholesterol, and 0.5% cholic acid); (2)
Apoe-deficient mice fed either a chow diet, a Western
diet (21% fat and 0.15% cholesterol), or a high-fat and
high-cholesterol diet without cholic acid; and (3) Ldlr-
deficient mice fed either a Western diet or a high-fat and
high-cholesterol diet. The latter twomodels are also called
sensitized models (Dansky et al., 2002). Some early QTL
studies took advantage of the existing recombinant inbred
lines, such as BXH and CXB (Paigen et al., 1987a, 1987b,
1987c). Since then, 14 different F2 or N2 crosses have
been generated to find atherosclerosis-regulating QTLs:
seven crosses have involved normal inbred mice, five
have involved inbred mice with Apoe deficiency, and
two have involved inbred mice with Ldlr deficiency (TableCell Metabolism 6, September 2007 ª2007 Elsevier Inc. 165
Table 1. Quantitative Trait Loci for Atherosclerotic Diseases in Humans
lies) Reference
Wang et al. (2004)
Fox et al. (2004)
Turner et al. (2005)
Gudmundsson et al. (2002)
Hauser et al. (2004)
Shiffman et al. (2005)
Wang et al. (2004)
Fox et al. (2004)
Shiffman et al. (2006)
Samani et al. (2005)
Pajukanta et al. (2000)
Wang et al. (2005a)
Harrap et al. (2002)
Farrall et al. (2006)
Hauser et al. (2004)
Francke et al. (2001)
Harrap et al. (2002)
Turner et al. (2005)
Shiffman et al. (2005)
Wang et al. (2004)
Wang et al. (2004)
Gretarsdottir et al. (2002)
Nilsson-Ardnor et al. (2005)
Zintzaras and Kitsios (2006)
Wang et al. (2005a)
Ozaki et al. (2002)
Lange et al. (2002)
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wChr Peak Cytogenetic Band (CI) Peak cM Peak Mb (CI) Nearest Marker LOD Disease Population (Individuals/Fami
1 1p36.13 (p36.21-34.2) 47 21 (13–41) D1S3669 11.7 MI US, 1613/428
1p33 (p35.2-31.3) 76 48 (31–61) D1S2134 2.4 CIMT US, 1242/311
1p31.3 (p32.3-31.1) 92 61 (52–80) 2.1 CAC US whites, 948/393 sibships
1p31.1 (p31.1-31.1) 102 71 (70–76) D1S2895 3.9 PAOD Icelanders, 116/272
1q31.1 (q24.2-32.1) 202 184 (164–200) D1S518 2.2 CAD international, 1168/438
1q44a 287 244 OR13G1 OR = 1.2 MI US whites, 3 case-control
studies
2 2p11.2 (p13.3-q12.2) 103 85 (70–106) D2S1790 3.3 MI US, 1613/428
2p11.2 (p13.3-q12.2) 103 85 (70–106) D2S1790 1.6 CIMT US, 1242/311
2p11.2a 103 86 rs1010 OR = 1.8 MI US, 3 case-control studies
2q14.3 (p11.2-q23.3) 134 128 (85–152) D2S2271 2.7 CAD UK, ?/1698
2q22.1 (q21.2-24.3) 150 142 (134–168) D2S129 3.2 CAD Finns, 364/156
2q34 (q33.3-35) 210 214 (205–221) D2S2944 3.1 CIMT Mexican Americans, 274/91
2q36-37.3 250 (221–243)b 2.6 ACS Australians, 61 sib pairs
3 3p26.1 (p26.3-25.3) 19 6 (0–9) 1.5 CAD Europeans, 1464 sib pairs
3q13.31 (p12.1-q22.1) 140 119 (86–134) D3S2460 3.5 CAD international, 1168/438
3q27.2 (q26.31-28) 199 187 (175–191) D3S1571-3686 2.4 MI Indo-Mauritians, 535/99
3q26-27 (162–190)b 1.8 ACS Australians, 61 sib pairs
4 1p16.1 (p16.3-15.33) 13 7 (0–15) 2.0 CAC US whites, 948/393 sibships
4q32.3a 170 170 PALLADIN OR = 1.3 MI US whites, 3 case-control
studies
4q34.1 (q32.2-35.1) 176 175 (162–185) D4S2431 4.4 MI US, 1613/428
5 5p14.3 (p15.2-13.2) 36 22 (10–34) D5S2845 3.7 MI US, 1613/428
5q12.1 (q11.2-12.1) 69 59 (57–61) D5S2080 4.4 Stroke Icelanders, 914/179
5q13.3 (p13.3-q14.3) 82 76 (33–83) D5S424 2.0 Stroke Northern Swedish, 117/56
6 6p22.3-21.1c (15–46) CAD/MI
6p22.1 (p22.3-12) 44 29 (19–65) D6S1022 2.2 CIMT Mexican Americans, 274/91
6p21.33a 45 32 LTA OR = 1.8 MI Japanese, 1133 MI, 1006
controls
6q12 (p21.1-q14.3) 83 72 (42–86) D6S1053 2.2 CAC US whites, 94/29 sibships
6 Shiffman et al. (2005)
7 7 Fox et al. (2004)
7 Wang et al. (2004)
8 8 Zintzaras and Kitsios (2006)
8 Zintzaras and Kitsios (2006)
9 9 Helgadottir et al. (2007);
McPherson et al. (2007);
Wellcome Trust Case
Control Consortium (2007)
10 1 Lange et al. (2002)
1 Francke et al. (2001)
11 1 Farrall et al. (2006)
12 1 Shiffman et al. (2005)
1 Fox et al. (2004)
1 Wang et al. (2004)
1 Fox et al. (2004)
13 1 Helgadottir et al. (2004)
1 Wang et al. (2005a)
1 Wang et al. (2004)
14 1 Zintzaras and Kitsios (2006)
1 Wang et al. (2004)
1 Fox et al. (2004)
1 Broeckel et al. (2002)
15 1 Wang et al. (2003a)
16 1 Francke et al. (2001)
17 1 Farrall et al. (2006)
1 Farrall et al. (2006)
19 1 Hauser et al. (2004)
1 Shiffman et al. (2006)
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wq22.1a 169 118 ROS1 OR = 1.2 MI US whites, 3 case-control
studies
p14.3 (p15.3-14.1) 50 31 (22–43) D7S817 1.6 CIMT US, 1242/311
q22.2 (q21.12-31.33) 114 104 (87–124) D7S1799 3.6 MI US, 1613/428
q13.2-22.2c (68–99) CAD/MI
q24.21-24.3c (127–140) CAD/MI
p21.3 38 22 Rs10757274 OR = 1.2–1.9 CAD/MI 10 different populations
0q22.2 (q21.3-23.2) 95 77 (64–88) D10S1432 3.2 CAC US whites, 94/29 sibships
0q23.33 (q23.2-26.11) 116 95 (86–119) D10S185 2.1 CAD Indo-Mauritians, 535/99
1p11.2 (p13-q13.1) 66 43 (35–63) 1.7 CAD Europeans, 1464 sib pairs
2p13.2a 22 11 TAS2R50 OR = 1.3 MI US whites, 3 case-control
studies
2q12 (p12.1-q13.2) 56 42 (21–55) D12S1301 1.7 CIMT US, 1242/311
2q24.33 (q24.31-24.33) 161 129 (124–132) D12S1045 4.4 MI US, 1613/428
2q24.33 (q24.31-24.33) 161 129 (124–132) D12S1045 4.1 CIMT US, 1242/311
3q12.3 (q12.12-14.11) 24 30 (23–42) D13S289 2.5 MI Icelanders, 713/296
3q33.3 (q31.1-34) 94 107 (80–109) D13S796 1.3 CIMT Mexican Americans, 274/91
3q33.3 (q32.3-34) 94 107 (98–110) D13S796 3.6 MI US, 1613/428
4p13-q13.1c (0–32) CAD/MI
4q23.1 (q21.3-24.3) 67 60 (49–73) D14S592 4.2 MI US, 1613/428
4q31.2 (q24.2-32.12) 92 83 (70–92) D14S606 1.8 CIMT US, 1242/311
4q32.2 (q32.2-32.31) 126 100 (98–101) D14S1426 3.9 MI Germans, 1406/513
5q26.3 (q26.2-26.3) 113 97 (96–99) D15S120 4.2 CAD/MI US, 21/1
6p13.3 (p13.3-13.2) 9 4 (0–8) D16S3027 3.1 CAD Indo-Mauritians, 535/99
7q11.2 (p12-q22) 51 23 (14–50) 2.9 MI Europeans, 739 sib pairs
7q21.2 (q12-22) 67 36 (32–50) 1.6 MI Europeans, 344 sib pairs
9p13.12 (p13.2-q13.11) 44 16 (9–40) D19S252 1.7 CAD international, 1168/438
9q13.2a 65 47 Rs11881940 OR = 1.9 MI US, 3 case-control studies
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.168 Cell Metabolism 6, September 2007 ª2007 Elsevier Inc.2). Thirty different mouse atherosclerosis QTLs have been
found: 15 in one cross, 11 in two different crosses, and 4 in
three or more crosses. Among the 30 atherosclerosis-
regulating QTL, 7 were found only in the high-fat model,
12 only in the Apoe-deficient model, 4 only in the Ldlr-
deficient model, 2 in both the Apoe-deficient and the
Ldlr-deficient models, and 5 in both the high-fat and the
sensitized models. Among the 30 QTLs, 13 are replicates
(the same QTL region found in different studies). A com-
parative map (Figure 2) of mouse and human atheroscle-
rosis-regulating QTLs indicates that most of the mouse
QTLs found in both the high-fat model (86%) and the
sensitized models (61%) are concordant with the human
QTLs. In all, 20 of the 30 mouse QTLs are concordant
with the human QTLs. This comparative QTL map will be
helpful in two ways. First, it will help researchers focus
on the concordant QTLs, because finding the underlying
genes in the mouse might facilitate finding them in hu-
mans. Second, by overlapping the concordant QTLs and
excluding the nonoverlapping regions, based on the as-
sumption that the same orthologous genes underlie the
QTLs in both species, we might be able to significantly
narrow many of the mouse QTLs. Of course, this assump-
tion may not always be true. Mouse QTLs can also be
narrowed via other bioinformatics methods, such as
combined-cross analysis, haplotype analysis, and whole-
genome association studies (DiPetrillo et al., 2005). Candi-
date genes can be analyzed for sequence and expression
patterns, and a shortened list of candidates can be verified
in animal models and in human association studies (Wang
et al., 2005b).
Two of the genes underlying mouse atherosclerosis
QTLs have been identified: Alox5 for the QTL Artles (arte-
rial lesions) on Chr 6, and Tnfsf4 (Ox40l) for the QTL Ath1
(atherosclerosis susceptibility 1) on Chr 1 (Table 2). Artles
was identified in a cross between CAST and C57BL/6
mice (Mehrabian et al., 2001). By usingAlox5 targetedmu-
tant mice with or without Ldlr deficiency,Alox5was shown
to increase atherosclerosis (Ghazalpour et al., 2006; Meh-
rabian et al., 2002). Other evidence that the ALOX5/
ALOX5AP pathway is involved in atherogenesis seems
compelling: genetic linkage and association studies in hu-
mans have revealed that ALOX5AP confers risk of MI and/
or stroke (Helgadottir et al., 2004, 2005; Kajimoto et al.,
2005a; Kaushal et al., 2007; Lohmussaar et al., 2005), pro-
moter variants of ALOX5 are associated with CIMT in hu-
mans (Dwyer et al., 2004), expression levels of ALOX5 are
elevated in symptomatic plaques and are associated with
acute ischemic syndromes (Cipollone et al., 2003; Qiu
et al., 2006), and ALOX5AP inhibitor reduces athero-
sclerosis in mice (Jawien et al., 2006). Because ALOX5
and ALOX5AP are involved in leukotriene formation, leu-
kotriene receptors and leukotriene-forming enzymes
have been studied for their role in atherosclerosis. It was
found that CP-105696, an LTB4 receptor antagonist, de-
creases atherosclerosis in both Apoe/ and Ldlr/
mouse models; this effect is dependent on the presence
of CCL2 (MCP-1) because the drug has no effect in
Ccl2/ mice (Aiello et al., 2002). In addition, targeted
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ReviewFigure 1. Chromosome Map of Human and Mouse Concordant Quantitative Trait Loci for Atherosclerotic Diseases
Human high-density lipoprotein cholesterol (HDL-C) quantitative trait loci (QTLs) are represented by bars to the left of each chromosome. Each bar
represents a QTL from one population as shown in Table 1. QTL sizes are given as either 1.5-LOD (logarithm of the odds ratio) drop intervals (if LOD
score figures are available) or ±15 cM centered around the LOD score peak (if LOD score figures are unavailable). Human homologs of mouse HDL-C
QTLs are represented by red bars to the right of each chromosome, and the chromosome numbers of these mouse QTLs are to their right.mutation of LTB4 receptor 1 (Ltb4r1) leads to reduced
early atherosclerosis (Heller et al., 2005; Subbarao et al.,
2004). Furthermore, a polymorphism of leukotriene A4
hydrolase (LTA4H), whose gene product hydrolyzes
LTA4 into the leukocyte chemoattractant LTB4, is associ-
ated with the risk of MI in an Icelandic cohort (Helgadottiret al., 2004). The above observations strongly suggest that
the ALOX5/ALOX5AP pathway influences the progress of
atherosclerotic disease.
However, it is noteworthy that conflicting data do exist.
In both Apoe/ and Ldlr/ mouse models, ALOX5 defi-
ciency did not significantly affect lesion development inCell Metabolism 6, September 2007 ª2007 Elsevier Inc. 169
Table 2. Quantitative Trait Loci for Atherosclerosis in Inbred Mouse Crosses
C s Reference
1 Paigen et al. (1987c);
Phelan et al. (2002)
N. Ishimori and B.P.,
unpublished data
Dansky et al. (2002)
2 1 Seidelmann et al. (2005)
8 Smith et al. (2006)
3 3 Smith et al. (2006)
a4 Teupser et al. (2006)
a3 Teupser et al. (2006)
4 Wang et al. (2003b)
Korstanje et al. (2004)
N. Ishimori and B.P.,
unpublished data
q1 Welch et al. (2001)
5 4 Smith et al. (2006)
6 s Mehrabian et al. (2001)
q2 Welch et al. (2001)
7 2 Colinayo et al. (2003)
Stewart-Phillips et al. (1989)
8 N. Ishimori and B.P.,
unpublished data
Colinayo et al. (2003)
N. Ishimori and B.P.,
unpublished data
9 N. Ishimori and B.P.,
unpublished data
K. Svenson and B.P.,
unpublished data
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whr Cross Peak Marker Peak cM (CI) Peak Mb (CI) LOD Locu
B 3 H and C 3 B RI lines D1Mit159 82 162 (151–170) Ath1
(B6 3 A) F2 1-169 Mb 100 178 (169–195) 3.4
(B6.129-Apoe/ 3 FVB.129-Apoe/) F2 D1Mit359 100 178(169–195) 3.3 Ath9
(PERA 3 B6.129-Ldlr/) 3 B6.129-Ldlr/ D2Mit405 69 148 (117–152) 2.8 Athla
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13476938 107 179 (174–179) 3.3 Ath2
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13477166 33 67 (53–89) 2.7 Ath2
(B6.129-Ldlr/ 3 FVB.129-Ldlr/) F2 D3Mit57 55 119 (90–131) 4.1 Ascl
(FVB.129-Ldlr/ 3 B6.129-Ldlr/) F2 D3Mit45 79 148 (141–160) 3.3 Ascl
(B6.129-Apoe/ 3 C3H.129-Apoe/) F2 D4Mit111 22 (3–50) 52 (10–102) 3.0
(SM 3 NZB) F2 D4Mit44 29 (18–51) 59 (46–104) 3.6 Ath8
(A 3 B6.129-Apoe/) F2 4-135 Mb 76 143 (136–154) 4.6
(MOLF 3 B6-Ldlr/) 3 B6-Ldlr/ D4Mit127 78 (66–81) 149 (136–151) 6.2 Aths
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13478585 84 147 (130–139) 3.4 Ath2
(CAST 3 B6) F2 D6Mit256 61 (46–71) 127 (105–144) 6.7 Artle
(MOLF 3 B6-Ldlr/) 3 B6-Ldlr/ D6Mit110 64 (52–70) 136 (115–143) 6.7 Aths
(B6 3 DBA/2) F2 D7Mit193 25 51 (33–68) 3.7 Aorls
A 3 B and B 3 A RI lines Tyr 44 (20–50) 87 (41–100) Ath3
(B6 3 A) F2 8-54 Mb 22 36 (31–67) 2.8
(B6 3 DBA/2) F2 D8Mit41 29 49 (39–88) 3.4
(A 3 B6.129-Apoe/) F2 8-109 Mb 60 120 (106–129) 2.0
(B6 3 A) F2 9-48 Mb 25 43 (34–63) 4.1
SWR 3 (SWR 3 SJL) D9Mit330 26 45 (36–66)
N. Ishimori and B.P.,
unpublished data
Su et al. (2006)
10 Ishimori et al. (2004)
Dansky et al. (2002)
N. Ishimori and B.P.,
unpublished data
Teupser et al. (2006)
N. Ishimori and B.P.,
unpublished data
Colinayo et al. (2003)
Ishimori et al. (2004)
11 Su et al. (2006)
Ishimori et al. (2004)
12 Mu et al. (1999)
Teupser et al. (2006)
Ishimori et al. (2004)
Teupser et al. (2006)
K. Svenson and B.P.,
unpublished data
Ishimori et al. (2004)
13 Smith et al. (2006)
14 Dansky et al. (2002)
N. Ishimori and B.P.,
unpublished data
15 Smith et al. (2006)
16 Dansky et al. (2002)
17 Smith et al. (2006)
18 Teupser et al. (2006)
(Continued on next page)
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w(A 3 B6.129-Apoe/) F2 9-64 Mb 42 74 (60–98) 3.7
(B6.129-Apoe/ 3 C3H.129-Apoe/) F2 D9Mit156 42 74 (60–98) 4.1 Ath22
(B6 3 129) F2 D10Mit213 10 (5–40) 19 (12–74) Ath20a
(B6.129-Apoe/ 3 FVB.129-Apoe/) F2 D10Mit213 11 (0–29) 20 (0–51) 5.1 Ath11
(A 3 B6.129-Apoe/) F2 10-27 Mb 12 22 (7–29) 2.8
(B6.129-Ldlr/ 3 FVB.129-Ldlr/) RpF2 D10Mit16 16 21 (14–43) 13.1 Ascla1
(B6 3 A) F2 10-27 Mb 20 26 (18–55) 3.9
(B6 3 DBA/2) F2 D10Mit42 30 (14–45) 55 (20–88) 4.5 Aorls1
(B6 3 129) F2 D10Mit31 34 (30–36) 67 (55–68) 6.6 Ath17
(B6.129-Apoe/ 3 C3H.129-Apoe/) F2 D11Mit236 20 44 (20–56) 2.4
(B6 3 129) F2 D11Mit333 60 (55–70) 99 (94–113) Ath19a
(B6-db/db 3 BKS) F2 D12Mit49 3 (2-4) 13 (9–15) 2.5 Ath6
(B6.129-Ldlr/ 3 FVB.129-Ldlr/) RpF2 D12Mit82 3 13 (0–39) 3.9 Ascla5
(B6 3 129) F2 D12Mit243 16 (13–17) 36 (32–38) 3.7 Ath18
(B6.129-Ldlr/ 3 FVB.129-Ldlr/) RpF2 D12Mit189 24 (0–34) 55 (0–79) 4.8 Ascla6
SWR 3 (SWR 3 SJL), SWR 3 SJL RI D12Mit158 38 (35–40) 85 (81–86) Ath7
(B6 3 129) F2 D12Mit7 50 (10–70) 103 (27–119) Ath21a
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13481782 26 43 (33–67) 2.8 Ath25
(B6.129-Apoe/ 3 FVB.129-Apoe/) F2 D14Mit60 15 (10–40) 45 (28–70) 2.5 Ath13
(A 3 B6.129-Apoe/) F2 14-52 Mb 22 55 (31–69) 2.6
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13482467 14 20 (10–29) 3.3 Ath22
(B6.129-Apoe/ 3 FVB.129-Apoe/) F2 D16Mit103 22 29 (13–45) 2.5
(AKR.129-Apoe/ 3 DBA/2.129-Apoe/)
RpF2
rs13482966 20 36 (33–54) 4.3 Ath26
(B6.129-Ldlr/ 3 FVB.129-Ldlr/) F2 D18Mit23 21 44 (21–57) 3.1
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.172 Cell Metabolism 6, September 2007 ª2007 Elsevier Inc.a study by Zhao et al. (2004), in contrast to the observa-
tions by Mehrabian et al. (Ghazalpour et al., 2006; Mehra-
bian et al., 2002). Apart from the differences in study
design (age of the mice, length of diet, methods for mea-
suring the lesions), theAlox5 knockout mice used by these
two different groups likely had different lengths of 129
flanking region, which may exert additional effects on ath-
erogenesis other than those of Alox5 itself. In fact, the
Alox5 region contains at least two, and maybe as many
as four, genes that affect atherosclerosis (Ghazalpour
et al., 2006). In addition, the association ofALOX5AP poly-
morphisms with MI and/or ischemic stroke has not been
confirmed in other studies (Koch et al., 2007; Meschia
et al., 2005; Zee et al., 2006). This ismost likely due to pop-
ulation/ethnic differences, as the associations are more
significant in Icelandic and less or not so in non-Icelandic
populations. Therefore, the ALOX5/ALOX5AP pathway
may confer ethnicity-specific risk for MI and stroke. None-
theless, the use of the relatively isolated Icelandic popula-
tion reveals that the ALOX5/ALOX5AP pathway influences
atherosclerotic disease. One possible mechanism is that
the macrophage ALOX5 cascade generates leukotrienes,
which then act on neighboring ECs (and possibly also
T cells and macrophages themselves), thereby activating
the release of CC andCXC chemokines, resulting in the re-
cruitment of inflammatory cells into the artery (Zhao et al.,
2004). Therefore, ALOX5 and ALOX5AP may be targeted
for treating human atherosclerotic disease.
The second atherosclerosis-regulating QTL gene found
in the mouse was Tnfsf4 (OX40 ligand). OX40 ligand
and its receptor OX40 belong to the TNF/TNFR superfam-
ily. OX40 is mainly expressed on activated T cells, and
OX40L is expressed on antigen-presenting cells (B cells,
dendritic cells, macrophages, and ECs) and T cells. The
function of the OX40-OX40L costimulatory pathway has
been studied in Ox40- (Kopf et al., 1999) and Ox40l-
deficient mice (Chen et al., 1999; Murata et al., 2000).
These studies demonstrated that OX40-OX40L interac-
tions are crucial for optimal T cell function and the gener-
ation of memory T cells by promoting the survival of
effector T cells after antigen priming (Sugamura et al.,
2004). BecauseOx40l is a candidate gene forAth1 (Paigen
et al., 1987c; Phelan et al., 2002), we studied the role of the
OX40/OX40L pathway in atherosclerosis. We found that
OX40L is expressed on ECs, macrophages, and lympho-
cytes in mouse atherosclerotic lesions. OX40L is proa-
therogenic in mice: Ox40l-deficient mice have smaller
lesions, and transgenic mice overexpressing Ox40l have
larger lesions than controls do (Wang et al., 2005c).
More recently, van Wanrooij et al. (2007) found that treat-
ing Ldlr/mice with antibody against OX40 reduces ath-
erosclerosis by 53%, supporting the proatherogenic role
of OX40L. Based on the mouse studies, we performed
candidate gene association studies and found that
OX40L may also influence atherosclerosis in humans: in
two independent populations, the less common allele of
SNP rs3850641 in OX40L was significantly more frequent
(p% 0.05) in individuals with myocardial infarction than it
was in controls (Wang et al., 2005c). More recently,
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ReviewFigure 2. Chromosome Map of Mouse
and Human Concordant Atherosclerosis
QTLs
A vertical black line represents each chromo-
some, with the centromere at the top. Genetic
distances in Mb from the centromere are
shown by the scale at the lower left of the fig-
ure. Mouse atherosclerosis QTLs are repre-
sented by bars to the left of each chromosome.
Each bar represents a QTL from one cross as
shown in Table 2. QTL sizes are given as
95% confidence intervals (CIs), 1.5-LOD drop
intervals (if 95% CIs are not available but
LOD score figures are available), or ±10 cM
centered around the LOD score peak (if neither
CIs nor LOD score figures are available). To
change cM into Mb, we found MIT markers at
the cM positions in MGI (http://www.
informatics.jax.org/) and retrieved their Mb
positions from the Ensembl Mouse Genome
Server NCBI m36. Mouse homologs of human
HDL-CQTLs are represented by red bars to the
right of each chromosome, and the chromo-
some numbers of these human QTLs are to
their right.polymorphisms ofOX40were found to be associated with
the risk of MI (Ria et al., 2006), confirming that the OX40/
OX40L pathway influences the risk ofMI. However, the un-
derlying mechanism is unclear. The OX40L expressed on
vascular ECs might bind to OX40 on lymphocytes, facili-
tating their activation and recruitment into the arterial
wall. Or, by reverse signaling, ligation of OX40L on vascu-
lar ECs, macrophages, and lymphocytes may induce the
production of chemoattractants, drawing and directing
leukocytes from the blood into atherosclerotic plaques
(Wang, 2006). This possibility is supported by the observa-
tion that interaction of recombinant OX40 with human um-
bilical vein ECs (HUVECs) induces the ECs to produce the
CC chemokine RANTES (CCL5) (Kotani et al., 2002), a
chemoattractant for monocytes and T cells. RANTES
may promote atherosclerosis: intraperitoneal injection ofthe RANTES receptor antagonist Met-RANTES reduces
the progression of atherosclerosis in Ldlr/mice, accom-
panied by decreased leukocyte infiltration into lesions
(Veillard et al., 2004). It is also possible that the engage-
ment of OX40L and OX40 may induce the production of
inflammatory cytokines, as shown in a recent study indi-
cating that the engagement of OX40L on human airway
smooth muscle cells (SMCs) with recombinant OX40 re-
leases IL-6, a proinflammatory cytokine, from these
SMCs (Burgess et al., 2004).
There is evidence that angiopoietin-like 3 (Angptl3) un-
derlies Ath8, an atherosclerosis-regulating QTL on mouse
Chr 4 (Korstanje et al., 2004):Angptl3 has three nonsynon-
ymous polymorphisms between NZB and SM, the paren-
tal strains of the cross revealing Ath8; ANGPTL3 inhibits
lipoprotein lipase activity and increases total plasmaCell Metabolism 6, September 2007 ª2007 Elsevier Inc. 173
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Reviewcholesterol and triglyceride levels (Koster et al., 2005);
ANGPTL3 binds to integrin avb3, suggesting that it plays
a role in angiogenesis and atherogenesis (Camenisch
et al., 2002); and polymorphisms of ANGPTL3 are associ-
ated with the size of coronary atherosclerotic plaques in
one human population (Korstanje et al., 2004).
Genome-wide Association Studies
Testing the association of a gene with atherosclerotic dis-
ease is usually motivated by existing pieces of evidence
that the gene might be involved in certain atherogenic
pathways. However, single-gene association studies are
notorious for their high incidence of false-positive findings
and low level of reproducibility. Recently, the advent of
dense SNPs, detailed haplotype information, and low-
cost and high-throughput genotyping has made it
possible to carry out unbiased whole-genome association
studies to find disease genes, including those for athero-
sclerosis. In a pioneering, large-scale, case-control asso-
ciation study of a Japanese population, Ozaki et al. (2002)
used 92,788 gene-based SNP markers across the ge-
nome and identified the association of LTA (lympho-
toxin-alpha) polymorphisms with susceptibility to MI.
This association with CAD/MI has been replicated in
some (Laxton et al., 2005; Mizuno et al., 2006; PROCAR-
DIS Consortium, 2004) but not other studied populations
(Clarke et al., 2006), suggesting a population-dependent
effect. Following the results of their initial study, Ozaki
et al. used an E. coli two-hybrid system and phage display
to show that the LTA protein binds to LGALS2 (lectin,
galactose-binding, soluble 2). They then found that an
SNP in LGALS2 is significantly associated with suscepti-
bility to MI in a Japanese population and that SMCs and
macrophages in these atherosclerotic lesions express
both LGALS2 and LTA (Ozaki et al., 2004). However, the
association of LGALS2 polymorphisms with MI was not
confirmed in a Caucasian population (Mangino et al.,
2006), which may be due to population heterogeneity.
More studies are needed to address this inconsistency.
More recently, prompted by the finding that binding of
LTA to its receptor strongly activates NF-kB, an important
regulator of pro- and anti-inflammatory genes and cell sur-
vival in atherosclerotic lesions (de Winther et al., 2005;
Monaco andPaleolog, 2004), by proteasomal degradation
of its inhibitory partner, IkB19, Ozaki et al. tested the asso-
ciation of a variation in the genes encoding proteasomal
proteins and the risk of MI (Mizuno et al., 2006). The study
revealed that a common SNP (rs1048990) in the protea-
some subunit alpha type 6 (PSMA6) gene confers risk of
MI. The association was confirmed in a second cohort of
867 MI and 1104 control subjects. The authors further
found that rs1048990 affects the transcription activity of
PSMA6 and that suppression of PSMA6 expression using
siRNA reduces the activation of NF-kB. These results
demonstrate that large-scale association studies can
quickly identify novel disease-causing genes (such as
LTA) and that, in combination with functional genomics
studies, additional disease genes (for example, PSMA6)
can be identified. Later, in a large-scale association study174 Cell Metabolism 6, September 2007 ª2007 Elsevier Inc.using 11,053 SNPs, Shiffman et al. (2005) found four gene
variants associated withMI (PALLD,KOS1, TAS2R50, and
OR13G1), and the association was confirmed in two addi-
tional populations. In another large-scale association
study using 11,647 SNPs, these authors found that
VAMP8 and HNRPUL1 were associated with risk of MI,
and the association was confirmed in two additional pop-
ulations (Shiffman et al., 2006). The possible functions of
these two genes in MI are not clear; VAMP7 may activate
platelets, thereby affecting MI. More recently, three differ-
ent studies, in which 100,000- to 500,000-SNP sets and
12 different populations were used, identified SNPs at
the same region (9p21.3, z22.1 Mb) that are associated
with CAD and MI (Helgadottir et al., 2007; McPherson
et al., 2007; Wellcome Trust Case Control Consortium,
2007). These SNPs are near CDKN2A and CDKN2B, two
tumor-suppressor genes.
Genome-wide association studies have also been used
in mice to find genes affecting plasma HDL cholesterol
levels (Pletcher et al., 2004). The availability of dense
SNP maps in more than 50 inbred mouse strains and
a better understanding of mouse haplotype structures
have greatly improved the feasibility and reliability of
such studies.
Genome-wide/large-scale association studies can help
find new atherosclerosis-regulating genes in three ways.
First, the few genes in a usually very narrow associated re-
gion can be confirmed and their functions determined in
separate populations. Second, an associated region can
be used to pinpoint candidate genes in a coincident QTL
and thereby facilitate identifying its underlying gene. Third,
some QTL regions can be selected for large-scale gene
association studies by testing dense SNPs in the region.
Using Linkage and Association Studies to Find
Atherosclerosis Genes in Mice and Humans:
Expectations, Limitations, and Future Directions
Traditional models of atherosclerosis have been useful in
shedding light on this complex disease, especially on
the early stages of atherogenesis. However, we need ac-
curate models for the clinical outcomes of plaque rupture,
which causes thrombotic occlusions and myocardial in-
farction. Additionally, Apoe- and Ldlr-deficient mutant
mice with genetic backgrounds other than C57BL/6
should be produced. The use of such strains along with
newly available bioinformatics tools will likely reveal novel
atherosclerosis QTLs and facilitate the identification of
their underlying genes (Wang et al., 2005b).
It is noteworthy that finding an atherosclerosis QTL
gene may subsequently reveal a new pathway for athero-
genesis. Even if the human ortholog of an atherosclerosis-
regulating mouse gene is not a good target, other genes in
the new pathways identified from genetics and genomics
may be.
According to our current knowledge, two major distur-
bances affect the progression of atherosclerosis: dyslipi-
demia and inflammatory response. Identifying their ge-
netic determinants may provide new therapies. The use
of mouse models to identify genes regulating plasma lipid
Cell Metabolism
Reviewlevels and atherosclerotic lesions has been reviewed re-
cently (Rollins et al., 2006; Wang et al., 2005b; Wang
and Paigen, 2005a, 2005b). Two genes identified in human
linkage studies of MI (ALOX5AP and MEF2A), the two
identified in mouse linkage studies of atherosclerosis
(Alox5 and Tnfsf4), and the two identified in human ge-
nome-wide association studies of MI (LTA and PSMA6)
are all involved in immune and inflammatory response
but are not involved directly in lipid metabolism. This
may not be a coincidence, because when atherosclerosis
or MI is used as an end point, the genes that are histori-
cally under selective pressure are easier to find. It is con-
ceivable that genes involved in defense against infection
(rather than those involved in influencing plasma lipid
and blood pressure levels) have been under greater selec-
tive pressure for human beings to reproduce and survive;
therefore, their polymorphisms are more tightly associ-
ated with inflammatory diseases (such as atherosclerosis)
and the associations are easier to find. This observation
that all of the six genes found are involved in inflammation
also suggests that genetic determinants of inflammatory
pathways account for a significant part of the population
variance of atherosclerotic disease incidence.
Genetic linkage, candidate gene association, and
genome-wide association studies all have their advan-
tages and limitations. Genetic linkage studies have been
very successful in finding genes for diseases with simple
Mendelian inheritance. However, although there have
been more and more successful examples in the last
few years (discussed above), finding human atherosclero-
sis genes via linkage studies remains difficult, and testing
the usually 100–200 genes in a QTL remains a daunting
task. The fact that only 3 out of the 40 QTLs for the
same atherosclerosis disease have been replicated and
that most of the variants identified from genome-wide
association studies are not in any previously found QTL
reflects the nature and complexity of atherosclerotic dis-
ease: etiological heterogeneity; many influencing genes,
each with very small effect; and the strong influence of en-
vironmental factors (lifestyle, diet, socioeconomic status,
etc). Adding to the complexity is the fact that genes affect-
ing a trait tend to be clustered in chromosomes and may
interact with each other to cause a change in the pheno-
type, making positional cloning difficult. As recently
shown in an elegant study by Ghazalpour et al. (2006),
a gene identified by positional cloning may not be the
only one that affects the phenotype of the QTL. By break-
ing the original Chr 6 CAST.B6 ‘‘congenic’’ region into 16
subregions, the authors found that, in addition to Alox5,
two to four other genes in the original Chr 6 QTL region af-
fect atherosclerosis. This suggests that the original con-
genic strain is not coisogenic and that the time-consuming
process of generating subcongenic lines is powerful for
finding bona fide QTL genes. ‘‘Peakwide mapping’’
(Wang et al., 2007), i.e., performing association studies
for genes in the QTL peak, as discussed above, should
be useful for identifying multiple causal genes for a QTL.
Using a mouse-human comparative genomics approach
should also increase the chance of finding human athero-sclerosis genes, as demonstrated in the case of OX40L
(Wang et al., 2005c). Candidate gene association studies
are more powerful and successful in testing whether the
gene of interest confers risk of atherosclerotic disease.
However, only genes suspected of affecting atherosclero-
sis will be tested (therefore, this approach is biased), and
significant association from one study needs to be con-
firmed in additional studies to exclude false positives,
which are often seen in candidate gene association stud-
ies. Another limitation of this approach is that the associ-
ation itself does not tell whether or how the polymor-
phisms affect the functions of the genes tested, such as
in the case of ALOX5, ALOX5AP, and OX40L. Ultimately,
functional studies in vitro and in vivo are needed to find
the causal polymorphisms and to evaluate the gene as
a new therapeutic target. As another unbiased approach,
the more recent genome-wide association studies have
been very successful in finding unexpected candidate dis-
ease genes, including those for atherosclerotic disease.
The availability of dense SNP sets will likely increase the
power of this approach further. However, at this time,
the cost of performing such studies is still high (millions
of dollars). Recent technological advances, most notably
rapid and low-cost microarray and genotyping methods,
have made it possible to treat gene expression data as
phenotypes and locate QTLs for them; these are so-called
expression QTLs (eQTLs). This allows quantification of the
expression of tens of thousands of genes simultaneously
in an unbiased manner. Combining eQTLs and traditional
clinical QTLs (cQTLs; for example, atherosclerosis and
HDLQTLs), candidate genes can be found for further test-
ing. For example, if a cis-eQTL is found within the interval
of a cQTL, the cis-eQTL gene would be a good candidate
for further testing (Hubner et al., 2005; Yaguchi et al.,
2005). Using this approach, Abcc6 was found as a causal
gene for dystrophic cardiac calcification in mice (Meng
et al., 2007). We can expect that new atherosclerosis-
related genes will be found using this approach in the
coming years.
Translating Genome Information into Medication
of Atherosclerosis: Future Perspectives
Researchers are hopeful that the sequencing of human
and model organism genomes, along with the many other
technological advances in biomedical research tools, will
lead to dramatic improvements in cardiovascular disease
therapies. Although two individuals may have the sameMI
symptoms, those symptoms may be caused by different
combinations of genetic and environmental factors and
may call for different therapies. As such, finding genetic
determinants for atherosclerotic disease is crucial for indi-
vidualized medication. Finding these genes and knowing
their functions will greatly facilitate drug target develop-
ment. Some of the genes and their products may also
be used as biomarkers for diagnosis and for stratifying
patients according to genetic risk factors in order to take
early preventive measures.
Recently, the deCODE investigators performed a ran-
domized, prospective, placebo-controlled, crossoverCell Metabolism 6, September 2007 ª2007 Elsevier Inc. 175
Cell Metabolism
Reviewphase II trial in 191 MI patients with at-risk variants of
either ALOX5AP or LTA4H to determine the therapeutic
effects of DG-031, an ALOX5AP inhibitor (Hakonarson
et al., 2005). In patients with specific at-risk variants of
these two genes in the leukotriene pathway, DG-031 ef-
fectively reduces LTB4 production by activated neutro-
phils and increases urinary leukotriene E4 levels. DG-
031 also suppresses three biomarkers of increased MI
risk (C-reactive protein, intercellular adhesion molecule,
and myeloperoxidase). This trial was the first to use
a gene-specific and individualized approach to treat ath-
erosclerosis, and these preliminary results illustrate the
potential to translate genomics information into novel
diagnostics and treatments.
Obviously, atherosclerotic disease is complex, and
a large amount of research is required before genetics
can be translated into clinical practice (Arnett et al.,
2007). The genetic approaches discussed in this review
will greatly accelerate the pace at which we acquire that
knowledge. Together with clinical data, this knowledge
will help us better understand cardiovascular pharmaco-
genetics and pharmacogenomics andwill facilitate the de-
velopment of individualized diagnosis, preventatives, and
treatments for atherosclerosis (Arnett et al., 2007).
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